• Rapport Therapeutics CEO Abraham Ceesay sold 2,210 common shares on Oct. 21, 2026, at $29.1618 per share.
• Following the sale, Ceesay directly owned 450,035 common shares.
• Indirect holdings included 81,729 common shares through the Ceesay Family Irrevocable Trust and 20,729 through the Dorothy Ceesay Irrevocable Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-430504), on October 23, 2026, and is solely responsible for the information contained therein.